{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Defined as the time from date of first dose of study treatment until the earliest date of disease progression (based on investigator assessment of per RECIST v1.1) or death due to any cause, if occurring sooner than progression.","groups":[{"description":"INCB001158 dosed at 50mg BID in combination with epacadostat (100 mg BID) and pembrolizumab (200 mg Q3W)","id":"OG000","title":"INCB001158 50mg BID+ Epacadostat + Pembrolizumab"},{"description":"INCB001158 dosed at 75mg BID in combination with epacadostat (100 mg BID)and pembrolizumab (200 mg Q3W)","id":"OG001","title":"INCB001158 75 mg BID + Epacadostat + Pembrolizumab"}],"populationDescription":"No patients were analyzed due to insufficient numbers and risk of identifying patient by reporting data on 1 person enrolled in cohort 2","reportingStatus":"POSTED","timeFrame":"Up to approximately 12 months per subject","title":"Progression-free Survival With INCB001158 in Combination With Epacadostat ± Pembrolizumab","type":"SECONDARY"}